Columbia Pacific University (CPU) was a non-traditional distance learning school in California. It was founded in 1978 by Richard Crews, a Harvard-trained psychiatrist, and Lester Carr, a former president of Lewis University, and operated with state approval. Distance learning and education authority John Bear gave "high marks" to the school in his 1982 Bears' Guide to Non-Traditional College Degrees, 8th edition.CPU was closed by California court order in 2000.California recognizes CPU degrees earned before June 25, 1997, as "legally valid" for use in the state. CPU degrees earned on or after June 25, 1997, are "not legally valid" for use in California.CPU alumni acquired all rights to the CPU name and registered a "Columbia Pacific University", a non-profit organization in Delaware.[citation needed] Until 2007, the CPU Press continued its publication program. CPU degrees earned on or after June 25, 1997, are "not legally valid" for use in California.
Parkinson's disease (PD) heterogeneity complicates disease-modification clinical trial design and lead to ambiguous results, necessitating robust subtyping frameworks to identify rapid progressors. This study compared progression milestones across previously defined clinical (tremor-dominant [TD], postural instability/gait difficulty [PIGD], indeterminate), pathological (brain-first, body-first), and data-driven (diffuse malignant [DM], intermediate [IM], mild motor-predominant [MMP]) PD subtypes. Using data from the Parkinson's Progression Markers Initiative (PPMI), we analyzed milestone attainment across six functional domains and performed Cox proportional hazards regression. Randomized controlled trial sample size simulations evaluated the impact of subtyping on trial efficiency. Data-driven subtypes exhibited the highest progression rates, with DM patients attaining 63.0% of milestones, surpassing PIGD (55.6%) and body-first (54.0%) subtypes. Cox proportional hazards regression confirmed that DM patients had the highest hazard of progression compared to MMP, after adjusting for age at enrollment. Trial power simulations demonstrated that enrolling DM patients could reduce sample size requirements by approximately 50% using standard trial durations compared to unstratified PD cohorts. This analysis showed that data-driven subtyping, particularly the identification of the DM subtype, offers a promising strategy to optimize disease-modification trials in PD by capturing patients who meet progression milestones earlier.
Background Biomarkers that are informative with regards to the degree of demyelination associated with disease activity in multiple sclerosis may aid in prognostication and treatment considerations. Protein components of myelin, such as myelin oligodendrocyte glycoprotein (MOG), are potential biomarkers of demyelination, but questions remain about the significance and utility of blood MOG protein levels in multiple sclerosis. Methods In a case-control study, MOG protein levels were compared in serum samples from individuals with multiple sclerosis and controls. Cerebrospinal fluid (CSF) MOG protein levels were measured in a subset of the cases. Serum neurofilament levels were also measured for comparison. Results Serum MOG protein levels were higher in individuals with multiple sclerosis than those with a primary headache diagnosis (non-inflammatory neurological controls) and healthy donors. ROC curve analysis indicated good discrimination between multiple sclerosis and controls based on serum MOG protein levels. Correlation between serum and CSF MOG protein levels was moderate. Higher MOG protein levels were associated with clinical disease activity in multiple sclerosis and incrementally added to information provided by serum NfL levels. There was a moderate correlation between serum MOG and serum NfL levels. Conclusion MOG protein levels are elevated in the blood of individuals with multiple sclerosis and may be associated with disease activity. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by grants from the ziMS Foundation and Mitchell Family Foundation ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Board of Virginia Commonwealth University gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors
BACKGROUND & AIMS:Alcohol is a leading global risk factor for more than 200 diseases, premature death, and disability. We aimed at updating the Alcohol Preparedness Index (API) to map global and regional policy trends between 2010 and 2019. METHODS:We compiled policy data from 141 countries from the World Health Organization Global Information System on Alcohol and Health and scored five domains: national policy frameworks; production, pricing, and taxation; marketing and availability; drink-driving countermeasures; and monitoring and surveillance. The primary endpoint was the percentage change in API between 2010 and 2019. We summarized trends by region and explored potential variables that explain these trends with an adjusted regression model. RESULTS:By 2019, fewer than 25% of countries had a strong national alcohol plan (defined as a written national policy accompanied by a formal action plan for its implementation), whereas 40% had none. Production, pricing, and taxation showed the clearest increase (27% in 2010 and 78% in 2019). Monitoring and surveillance reached strong levels at 47.5%. The median API increased from 57.0 (39.0-82.0) in 2010 to 74.8 (58.3-83.5) in 2016, remaining above baseline in 2019 at 67.8 (51.2-83.8). Larger population size negatively correlated with API change (β = -19.1, p <0.05). Human Development Index and alcohol per capita consumption were not significantly associated with API change. CONCLUSIONS:From 2010 to 2019, preparedness on alcohol policy increased globally, though progress remained uneven across domains and regions. These findings highlight persistent policy gaps and support the prioritization of evidence-based interventions aligned with the SAFER framework. Future efforts should focus on translating policy presence into implementation, with particular attention to domains most strongly linked to alcohol-associated liver disease outcomes. IMPACT AND IMPLICATIONS:Despite the well-established harms of alcohol, global trends in alcohol policy preparedness remain poorly characterized. Using the validated Alcohol Preparedness Index across 141 countries, we demonstrate meaningful but uneven global progress between 2010 and 2019, with gains concentrated in taxation and monitoring domains, whereas national planning and marketing controls lagged, particularly in low-income regions. These findings are directly relevant to policymakers and public health authorities, as stronger alcohol policy environments have previously been linked to lower rates of alcohol-associated liver disease, hepatocellular carcinoma, and cardiovascular mortality. Within the limitations of an ecological study design, this work provides a practical roadmap for identifying policy gaps and prioritizing interventions aligned with the WHO SAFER framework to reduce the global burden of alcohol-related disease.
In this manuscript and in commemoration of the 1975 Children’s Defense Fund Report, we critique the use of “controlling for poverty” on racial disparities in school discipline in educational research, contending that this method problematically minimizes the role of systemic racism and historical inequities. To ground this argument, we utilize the backdrop of the economic disadvantages deeply intertwined with race due to centuries of racial oppression. To provide a more accurate and nuanced understanding of educational inequities, we advocate for re-evaluating poverty as a proxy for historical racism through including both current systemic factors and historical racism in analyses.
The assessment of comatose ICU patients presents several challenges with respect to the etiology, depth and ultimate outcome. The acceptance in 1959 of the worst-outcome scenarios of coma, i.e. brain death, and the publication of the Harvard Brain Death Criteria in 1968, were key developments in the management of irreversible coma. Pharmacologic confounders often complicate coma assessments, including brain-death determination. Moreover, associated clinical factors during coma, such as organ failure, hypothermia, prolonged continuous infusions, intoxication, and extreme obesity often alter drug metabolism and clearance. Such circumstances may further complicate standard assessments, and guideline recommendations often do not account for altered pharmacokinetics and pharmacodynamics. The assessment of comatose patients involves complex pharmacologic considerations that significantly impact diagnostic accuracy. Accurate differentiation between pharmacologic, metabolic, and structural causes of coma is essential, particularly since drug-related unconsciousness generally carries a more favorable prognosis than other etiologies. Nonetheless, for best outcomes, it is imperative that the etiology of any drug-induced coma be determined as early as possible. It is important to recognize, however, that routine toxicology screens are not comprehensive. Additionally, the interplay between hypothermia and drug metabolism poses unique challenges, as core temperature significantly affects pharmacokinetic parameters such as hepatic metabolism, leading to reduced drug clearance. Multiorgan dysfunction, common after severe neurological injury, further complicates these assessments. Overdose scenarios introduce additional complexity. While ancillary testing may aid in diagnosis of brain death, they have limitations, particularly in cases of profound intoxication. Additionally, premature use of ancillary testing could lead to misdiagnosis. This review is organized into two main sections: Part I examines general coma and its associated pharmacologic considerations, followed by Part II which focuses on brain death. Accurate assessment of coma and brain death often requires a multidisciplinary approach, integrating expertise in neurology, pharmacy, critical care, and toxicology. Current brain death guidelines provide a framework but leave open critical gaps in pharmacologic and toxicologic confounders. This review article highlights the importance of multidisciplinary approach to the care of coma and brain death patients and further research to refine diagnostic accuracy and mitigate the risks of premature brain death declarations.